Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.69 |
| ▸ | HTR2C | P28335 | 7/20 | 0.56 |
| ▸ | HTR2A | P28223 | 6/20 | 0.56 |
| ▸ | HTR2B | P41595 | 5/20 | 0.56 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 2/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL383414 | 0.98 | PNMT (0.67) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| Bromide SCHEMBL949591 | 0.98 | PNMT (0.67) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| Hydrochloric Acid SCHEMBL16033643 | 0.95 | PNMT (0.64) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL532012 | 0.82 | PNMT (0.85) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL329775 | 0.82 | PNMT (1.00) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL29543416 | 0.82 | ASIC3 (0.56) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL29587836 | 0.82 | PNMT (1.00) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| Hydrochloric Acid SCHEMBL947776 | 0.81 | PNMT (0.81) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| Hydrochloric Acid SCHEMBL1124954 | 0.81 | PNMT (0.96) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL25207974 | 0.79 | PNMT (0.79) | PNMTHTR2CHTR2AHTR2BASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3704125-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2024260464-A1 | PI3K INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4433059-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | Erasca, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-114072398-B | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-11939320-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4291177-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-1162424-C | Quinoline-4-radical derivative II | - | 2004-08-18 | — | — | CN | disclosed |
| EP-1343796-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002034760-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-02 | — | — | WO | disclosed |
| US-6339093-B1 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-01-15 | — | — | US | disclosed |
| CN-1304936-A | Quinoline-4-radical derivative II | HOFFMANN LA BOCHE & CO AG F (CH) | 2001-07-25 | — | — | CN | disclosed |
| EP-1090917-A1 | Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| US-5726197-A | ADRENORECEPTORS AND ADMINISTERING | SYNTEX (U.S.A.) INC. (US) | 1998-03-10 | — | — | US | disclosed |
| US-5026856-A | Bactericides | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1991-06-25 | — | — | US | disclosed |
| EP-0343560-A2 | Isoindoline derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
| EP-0056144-A1 | Carboxylic acid derivatives, their preparation and use as pharmaceuticals | Dr. Karl Thomae GmbH (DE) | 1982-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | PNMT 2917/4885HTR2C 2564/4885HTR2A 2807/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | PNMT 2804/4885HTR2C 4007/4885HTR2A 4112/4885 |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | PNMT 4852/4885HTR2C 1517/4885HTR2A 1239/4885 |
| US-11939320-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | PNMT 1437/4885HTR2C 1925/4885HTR2A 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.